To print: Select File and then Print from your browser's menu

Title: Lorus Announces the Presentation of Virulizin Phase 3 Clinical Trial Results in Pancreatic Cancer Including New Data from an Exploratory Analysis

"Lorus Announces the Presentation of Virulizin Phase 3 Clinical Trial Results in Pancreatic Cancer Including New Data from an Exploratory Analysis"

Clinical results presented at a major international oncology conference - TORONTO, CANADA -- February 1, 2006 -- Lorus Therapeutics Inc., a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products and technologies for the management of cancer, today announced the results of further exploratory analysis of data from its phase 3 clinical trial of Virulizin(R) for the treatment of pancreatic cancer. This analysis showed significant survival benefit for a subgroup of patients who continued to receive Virulizin after entering optional Stage 3(x) second-line therapy. Results of the phase 3 clinical trial, including data from further exploratory analysis, were presented orally today by Dr. Bruce Silver, FACP, Vice President, Oncology, Global Product Development Services at the 17th International Congress on Anti-Cancer Treatment (ICACT(xx)) in Paris, France. Dr. Silver is a medical oncologist with PRA International, which has provided the medical overview of this trial for the past four years. The randomized, double-blind, multicenter phase 3 clinical trial compared Virulizin plus gemcitabine to placebo plus gemcitabine for the treatment of chemonaive patients with locally advanced or metastatic pancreatic cancer as first-line therapy. Optional Stage 3 second-line therapy included continuation of Virulizin or placebo alone or in combination with 5-flurouracil. Top-line results from the trial were made public in October 2005. Virulizin did not demonstrate statistical significance in overall median survival in first-line treatment analysis, but promising median survival differences were observed in patient subgroups, including patients with metastasis and patients with low Eastern Cooperative Oncology Group (ECOG(xxx)) performance status. Virulizin treatment was well tolerated with no major differences observed between the Virulizin plus gemcitabine arm and the control group. Exploratory analysis of the clinical trial data, presented today, indicates a significant survival benefit for patients who entered optional second-line therapy after disease progression (Stage 3 in the clinical protocol) and who continued to receive Virulizin. Stage 3 patients who remained on Virulizin demonstrated a median survival of 10.9 months, compared with 7.4 months for both intent to treat (ITT) and efficacy evaluable (EE) patients on placebo. Differences in survival times were found to be statistically significant, with P values of 0.0178 and 0.0190 in the ITT (N equals 167) and EE (N equals 157) populations, respectively. Notably, the majority of Stage 3 patients from the Virulizin plus gemcitabine group chose to remain on Virulizin, comprising about 35% to 40% of the overall ITT or EE patient population in the trial. "Virulizin significantly improved survival in pancreatic cancer patients who remained on the treatment arm even when treatment with the standard-of-care chemotherapy gemcitabine was no longer effective," said Dr. Jim Wright, CEO of Lorus. "Lorus is committed to developing innovative, well- tolerated therapies for the management of cancer and we are encouraged by this new data. Although this finding is from exploratory analysis and in our view, will not be sufficient for regulatory approval without additional clinical investigation, it provides important new information for further clinical development strategies." Pancreatic cancer is a leading cause of cancer death in North America. It is usually diagnosed at a late stage and the survival rate is very poor. Approximately 35,000 North Americans are diagnosed with pancreatic cancer annually. REFERENCES: (x) Stage 3 patients are those who entered optional second-line therapy, and were offered Virulizin / placebo plus 5-flurouracil, or Virulizin / Placebo alone, or best supportive care (xx) ICACT is an international meeting for the discussion and presentation of state of the art developments in the management of cancer. (xxx) ECOG performance status is an internationally accepted scale that provides a rating of the health status of a cancer patient, using a scale of 0 to 5. A lower number indicates better health than a higher number. SOURCE: Lorus Therapeutics Inc.

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.